Effects of 2-Deoxy-glucose (2DG) with cisplatin and pemetrexed in mesothelioma cell mediated collagen gel contraction.
I. Gerogianni (Larissa, Greece), R. Jagirdar (Larissa, Greece), E. Pitaraki (Larissa, Greece), O. Kouliou (Larissa, Greece), C. Hatzoglou (Larissa, Greece), K. Gourgoulianis (Larissa, Greece), S. Zaroginannis (Larissa, Greece)
Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Gerogianni (Larissa, Greece), R. Jagirdar (Larissa, Greece), E. Pitaraki (Larissa, Greece), O. Kouliou (Larissa, Greece), C. Hatzoglou (Larissa, Greece), K. Gourgoulianis (Larissa, Greece), S. Zaroginannis (Larissa, Greece). Effects of 2-Deoxy-glucose (2DG) with cisplatin and pemetrexed in mesothelioma cell mediated collagen gel contraction.. 3800
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
2-Deoxy-glucose synergizes with Cisplatin and Pemetrexed chemotherapeutics to reduce cell migration of mesothelioma cells Source: International Congress 2019 – Pleural disease: applying the evidence Year: 2019
A comparison between the toxic side effects of adriamycin, cyclophosphamide, and etoposide (ACE) and carboplatin with etoposide (CbE) in the treatment of small cell lung cancer (SCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003
Effects of Cisplatin and Pemetrexed on the cell viability and cell adhesion of benign mesothelial and mesothelioma cells. Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Interplaying between Gamma-H2AX and autophagy in A549 cells treated with cisplatin and etoposide Source: International Congress 2017 – Lung cancer: latest basic research on molecular alterations, tumour-immune system-microenvironment interplay and the metabolome Year: 2017
A phase III randomised study comparing concomitant standard cisplatin (P) – etoposide (E) and chest irradiation to concomitant etoposide plus daily cisplatin and chest irradiation as induction therapy for limited (LD) small cell lung cancer (SCLC) Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Treatment of advanced and metastatic non small cell lung carcinoma (NSCLC) with a new schedule of gemcitabine (GEM) plus cisplatin (CDDP) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002
Comparison of vinorelbine containing dublet versus triplet schedule (vinorelbine cisplatin versus vinorelbine-ifosfamide cisplatin) in NSCLC Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001
First line treatment with gemcitabine plus cisplatine in non-small cell lung cancer: a comparison with etoposide plus cisplatin Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
Sequential monochemotherapy: vepesid (VP16) and carboplatin (CBDCA) in the treatment of elderly patients with small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001
A Phase II study of induction carboplatin (CBDCA) and docetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
The effectiveness of vinorelbine plus cisplatin versus gemcitabine plus cisplatin in local advanced non small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006
Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1α Source: Eur Respir J 2008; 32: 443-451 Year: 2008
Effectivity of chemotherapy regimen included carboplatin, ifosfamide, etoposide with or without adding interferon alpha 2a in treatment of patients with small cell lung carcinoma Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
New induction (Ind), gemcitabine (G), docetaxel (D) and cisplatin (C) followed by concomitant (Con) chemoradiotherapy in stage IIIB non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008
Gemcitabine and carboplatin (GC) versus mitomycin, ifosfamide and cisplatin (MIP): a phase III randomised comparison in stage IIIb or IV non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002
A phase 2 study of induction carboplatin (CBDCA) and dosetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 375s Year: 2001
Pegylated liposomal doxorubicin HCl (Caelyx) in combination with sandostatin LAR as salvage therapy in patients with small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Non-small cell lung cancer treatment: chemotherapy combination gemcitabine – cisplatin – paclitaxel Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Pegylated liposomal doxorubicin compared with traditional doxorubicin in combination chemo-radiotherapy for small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 465s Year: 2002
Generating senescent airway epithelial cell populations using low-concentration doxorubicin or etoposide Source: Virtual Congress 2021 – Advanced in vitro models for drug discovery Year: 2021